Swedbank AB Makes New $7.48 Million Investment in Medpace Holdings, Inc. (NASDAQ:MEDP)

Swedbank AB bought a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 22,400 shares of the company's stock, valued at approximately $7,477,000. Swedbank AB owned approximately 0.07% of Medpace at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Rise Advisors LLC bought a new position in Medpace in the 1st quarter worth $27,000. Mather Group LLC. acquired a new position in shares of Medpace during the 1st quarter worth about $28,000. Fidelis Capital Partners LLC bought a new stake in Medpace during the 1st quarter valued at approximately $31,000. DT Investment Partners LLC acquired a new stake in Medpace in the 2nd quarter valued at approximately $41,000. Finally, J.Safra Asset Management Corp increased its position in Medpace by 87.0% in the 1st quarter. J.Safra Asset Management Corp now owns 101 shares of the company's stock worth $41,000 after buying an additional 47 shares during the period. Institutional investors and hedge funds own 77.98% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Guggenheim lowered their price objective on shares of Medpace from $464.00 to $432.00 and set a "buy" rating on the stock in a research note on Wednesday, July 24th. StockNews.com downgraded shares of Medpace from a "buy" rating to a "hold" rating in a report on Friday, September 27th. Deutsche Bank Aktiengesellschaft reduced their target price on shares of Medpace from $395.00 to $336.00 and set a "hold" rating for the company in a research note on Wednesday, July 24th. TD Cowen decreased their target price on Medpace from $452.00 to $434.00 and set a "buy" rating on the stock in a research report on Wednesday, July 24th. Finally, Truist Financial cut their price target on Medpace from $415.00 to $397.00 and set a "hold" rating for the company in a report on Monday. Five research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, Medpace presently has a consensus rating of "Moderate Buy" and a consensus price target of $394.00.

Medpace Trading Up 3.9 %

Shares of Medpace stock traded up $13.51 during mid-day trading on Friday, reaching $356.40. 364,921 shares of the stock were exchanged, compared to its average volume of 264,610. The company has a market cap of $11.04 billion, a price-to-earnings ratio of 35.81, a price-to-earnings-growth ratio of 1.77 and a beta of 1.35. Medpace Holdings, Inc. has a fifty-two week low of $227.21 and a fifty-two week high of $459.77. The firm has a 50-day simple moving average of $357.03 and a 200 day simple moving average of $383.79.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its earnings results on Monday, July 22nd. The company reported $2.75 EPS for the quarter, topping the consensus estimate of $2.54 by $0.21. Medpace had a return on equity of 55.14% and a net margin of 16.74%. The business had revenue of $528.10 million for the quarter, compared to the consensus estimate of $528.41 million. During the same period in the previous year, the business earned $1.93 EPS. Medpace's revenue was up 14.6% compared to the same quarter last year. On average, research analysts predict that Medpace Holdings, Inc. will post 11.64 EPS for the current fiscal year.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.